Find your next paid study

OHSU Knight Cancer InstituteNCT07089940

~$10 – $7,500

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability,…

Avistone Biotechnology Co., Ltd.NCT06716138

~$10 – $8,750

SarcomaSarcoma, EwingDesmoplastic Small Round Cell Tumor+3 more

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

This research is being done to test a new drug called PEEL-224 in combination with two commercially available drugs, Vincristine and Temozolomide, and to deter…

David S Shulman, MDNCT06709495

~$10 – $7,500

Extensive Stage Lung Small Cell CarcinomaStage IV Lung Cancer

(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)

This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation \[TBI\]) and higher …

Vanderbilt-Ingram Cancer CenterNCT06110572

Observational

Optimizing Behavioral Health Services Following Pediatric Trauma Exposure

The goal of this clinical trial is to test the extent to which different treatment components work to improve pediatric post-traumatic stress disorder (PTSD). …

PTSDTraumaPediatric ALL

University of RochesterNCT06956781

Tetralogy of FallotDouble Outlet Right Ventricle

Mechanistic Clinical Trial of Beta-Blocker Administration For Reactivating Cardiomyocyte Division In Tetralogy of Fallot

Heart failure is a common long-term complication in patients with congenital heart disease (CHD). Medical treatments to promote regeneration of new healthy hea…

Weill Medical College of Cornell UniversityNCT04713657

Locally Advanced Solid TumorMetastatic Solid Tumor

A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and…

Non Small Cell Lung CancerEsophageal CancerGastric Cancer+3 more

~$10 – $8,750

Nuvalent Inc.NCT06521554

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despit…

University of Missouri-ColumbiaNCT03551951

~$10 – $750

Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer

A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targ…

Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more

University of Colorado, DenverNCT03042221

~$10 – $750

Phase 2

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have …

Non-small Cell Lung Cancer Stage IIINon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer+1 more

Case Comprehensive Cancer CenterNCT07104630

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

A Phase I Study of Osimertinib, Cetuximab, and Tucatinib in Advanced EGFR-Mutant NSCLC With Acquired Resistance to Osimertinib

This phase I trial tests the safety, side effects, and best dose of osimertinib, cetuximab, and tucatinib in treating patients with EFGR-mutant non-small cell …

Jonathan RiessNCT06067776

~$10 – $7,500

PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.

The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are goi…

Non Small Cell Lung CancerHealthy